Antibody–Drug Conjugates in Cancer Therapy: Current Landscape, Advances, and Future Directions

Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion [1][2]

In this review, we synthesize the structural fundamentals of ADCs—antibody formats, linker chemistry, payload selection—and their integrated mechanisms of action. We trace technological progression across three generations, summarize key breakthroughs and challenges, and highlight how innovations in conjugation strategies, linker design, and payload engineering have transformed the field. Notably, recent advances have led to pivotal changes in the treatment of breast and lung cancers, exemplified by agents such as trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan. [2][3] We also discuss the emergence of new modalities, such as degrader-antibody conjugates (DACs), and explore next-generation ADC designs and future directions for research and development [3]

Major Advances and Unmet Medical Needs
Despite advances in cancer management, malignant tumors remain a leading cause of morbidity and mortality worldwide. Traditional chemotherapies, though potent, are hampered by systemic toxicities and lack of selectivity, resulting in suboptimal outcomes for many patients.

Advertisement #3 

 

The advent of molecular oncology and antibody engineering has driven the search for strategies that maximize selectivity while retaining potent cytotoxicity. In this context, ADCs have emerged as one of the most promising modalities for targeted cancer therapy, translating Paul Ehrlich’s ‘magic bullet’ concept into clinical reality.[4]

Clinical Impact in Breast and Lung Cancer
The transformative impact of ADCs is particularly evident in the management of breast and lung cancer. In breast cancer, successive generations of ADCs—from ado-trastuzumab emtansine (T-DM1) to trastuzumab deruxtecan and sacituzumab govitecan—have improved outcomes across HER2-positive, HER2-low, and triple-negative subtypes. Landmark clinical trials (EMILIA, HER2CLIMB-02, DESTINY-Breast03/04/06, ASCENT, TROPiCS-02) have established ADCs as pivotal therapies, demonstrating improved survival and reduced toxicity compared with conventional chemotherapy.[4]

In lung cancer, ADCs targeting HER2, HER3, and TROP-2 (e.g., trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan) have shown promising objective response rates and manageable toxicity in both NSCLC and SCLC. Clinical experience underscores ADCs’ potential to become a cornerstone of lung cancer therapy, especially as precision oncology advances.[2]

Structural Fundamentals and Mechanism of Action
ADCs consist of three key components:

• Monoclonal antibody (mAb): Confers tumor selectivity via recognition of tumor-associated antigens.
• Cytotoxic payload: Orders of magnitude more potent than conventional chemotherapeutics.
• Chemical linker: Enables stable conjugation and regulated intracellular release.

Upon intravenous administration, ADCs bind cell surface antigens and undergo receptor-mediated endocytosis. Lysosomal trafficking results in payload release—via linker cleavage or antibody degradation—thereby triggering apoptosis by interfering with essential cellular processes, such as microtubule function or DNA replication. Membrane-permeable payloads can induce a ‘bystander effect,’ diffusing to kill adjacent tumor cells regardless of antigen status.[4]

Antibody Targets
The antibody component of ADCs determines target specificity and internalization. Most approved ADCs use humanized IgG1, balancing low immunogenicity, long half-life, and efficient immune engagement. Fc engineering (e.g., Fc-silenced variants) is increasingly employed to modulate effector function and reduce off-target uptake.

Ideal ADC antibodies bind tumor-associated antigens with high specificity and limited expression on normal tissue. Current ADCs target markers such as CD33, CD30, HER2, CD22, CD79b, Nectin-4, BCMA, EGFR, CD19, tissue factor (TF), and folate receptor-α (FRα). Ongoing efforts are expanding target space through bispecific/multispecific antibodies and novel antigens, addressing tumor heterogeneity and resistance.

Linker Chemistry
Linkers are central to ADC safety and efficacy, ensuring plasma stability and efficient intracellular payload release. Advanced linker strategies include acid-labile, enzyme-labile, and disulfide-cleavable bonds, engineered for precise payload release in tumor microenvironments. They are broadly categorized as:

• Non-cleavable linkers (e.g., SMCC thioether): Payload is only released after full antibody degradation in lysosomes, yielding minimal bystander effect (e.g., Trastuzumab emtansine (Kadcyla®; Genentech/Roche)).
• Cleavable linkers:
  • Chemically triggered (e.g., disulfide, hydrazone): Disulfide linkers are reduced by intracellular glutathione; hydrazone linkers are acid-labile and cleaved in endosomes/lysosomes.
  • Enzyme-dependent (e.g., peptide, glucuronide, galactosidase): Peptide linkers (e.g., Val–Cit–PABC) are cleaved by lysosomal proteases; other linkers are tuned to tumor-associated enzymes or microenvironmental factors for selective payload release.

The choice of linker determines not only stability and release but also the potential for bystander killing and therapeutic index.

Payload Design
Payloads have expanded beyond microtubule inhibitors (auristatins, maytansinoids) to include topoisomerase inhibitors, DNA alkylators, and emerging classes such as splicing modulators, protein degraders, and immunomodulators.[1][3] Payload classes include:

• Microtubule-disrupting agents:
  • Auristatins (MMAE/MMAF): Inhibit tubulin polymerization, causing mitotic arrest (e.g., brentuximab vedotin).
  • Maytansinoids (DM1/DM4): Block microtubule assembly (e.g., Kadcyla, mirvetuximab soravtansine).
  • Tubulysins, eribulin, cryptomycins, Eg5 inhibitors: Novel classes offering unique mechanisms or resistance profiles.
• DNA-damaging agents:
  • Calicheamicins, PBD/IBD dimers, duocarmycins: Induce DNA crosslinks or strand breaks.
  • Topoisomerase I inhibitors (SN-38, deruxtecan/DXd, exatecan): Trap topoisomerase I-DNA complexes, causing DNA damage (e.g., trastuzumab deruxtecan, sacituzumab govitecan).
  • Topoisomerase II inhibitors (doxorubicin, PNU-159682): Target DNA replication machinery.
• Emerging payloads:
  • Bcl-xL inhibitors, splicing modulators, NAMPT inhibitors, proteasome inhibitors, RNA polymerase II inhibitors (amatoxins), proteolysis targeting chimeras (PROTAC), immune agonists (ISACs), peptide–drug conjugates, photoimmunotherapy agents, radionuclides.

Payload selection is informed by potency, stability, conjugation compatibility, resistance profile, and the intended therapeutic indication.

Evolution of ADC Technology

• First-generation ADCs: Relied on murine antibodies and unstable linkers, resulting in poor efficacy and high immunogenicity (e.g., gemtuzumab ozogamicin). These limitations drove the development of more robust constructs.
• Second-generation ADCs: Introduced more stable linkers (e.g., thioether or protease-cleavable), and ultra-potent cytotoxins such as auristatins (e.g., monomethyl auristatin E (MMAE; e.g., brentuximab vedotin) or maytansinoids DM1 (e.g., trastuzumab emtansine). Tumor selectivity and pharmacokinetics improved, but challenges such as off-target toxicity and a heterogeneous drug-to-antibody ratio (DAR) persisted. Second-generation ADCs have improved pharmacokinetics and reduced toxicity. Trials such as EMILIA and HER2CLIMB-02 confirmed survival benefits in breast cancer.[4]
• Third-generation ADCs: Feature site-specific conjugation, higher and more homogeneous drug-to-antibody ratios or DAR (e.g., THIOMAB, noncanonical amino acids, enzyme-mediated methods), and potent payloads capable of bystander killing. Trastuzumab deruxtecan and sacituzumab govitecan exemplify this progress, with efficacy demonstrated even in tumors with low antigen expression (DESTINY-Breast03/04/06, ASCENT, TROPiCS-02).[4]

Expanding the ADC Modality: Degrader-Antibody Conjugates (DACs)
An emerging frontier is the development of DACs that couple monoclonal antibodies to proteolysis-targeting chimeras (PROTACs) or other protein degraders. DACs enable targeted degradation of intracellular proteins not accessible to traditional ADC payloads, broadening the therapeutic landscape and offering new mechanisms to overcome resistance.[3]

Challenges and Future Directions
Current Challenges

• Off-target toxicity: Premature drug release or low-level antigen expression can cause adverse events, including myelosuppression and neuropathy.
• Tumor heterogeneity and resistance: Variable antigen expression, impaired internalization, or increased efflux can limit efficacy.
• Pharmacokinetic and manufacturing hurdles: Heterogeneous DAR, immunogenicity, and complex conjugation require rigorous quality control.

Emerging Solutions

• Bispecific/multispecific ADCs: Target multiple antigens to address tumor heterogeneity.
• Smart linkers: Respond to tumor-specific stimuli to release payloads precisely.
• Novel payloads: Immunomodulators, protein degraders, and radiopharmaceuticals are broadening therapeutic impact.
• Combination therapies: Synergy with immune checkpoint inhibitors, chemotherapy, or radiotherapy is enhancing efficacy.
• Personalized medicine: Predictive biomarkers and patient selection maximize clinical benefit. [1]

Conclusion
Antibody–drug conjugates exemplify the convergence of molecular biology, immunology, and medicinal chemistry in precision oncology. Successive generations of ADCs have addressed key limitations, with site-specific conjugation, advanced linker chemistry, and innovative payloads driving breakthroughs across multiple cancer types. The emergence of new modalities such as DACs further expands therapeutic possibilities.

Ongoing technological and clinical innovations are set to enhance the selectivity, efficacy, and personalization of cancer treatment, fulfilling and extending Ehrlich’s vision of the ‘magic bullet’ in modern oncology.

Reference
[1] Chen B, Zheng X, Wu J, Chen G, Yu J, Xu Y, Wu WKK, Tse GMK, To KF, Kang W. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025 Nov 3;24(1):279. doi: 10.1186/s12943-025-02489-2. PMID: 41184856; PMCID: PMC12581584.
[2] Tawfiq RK, Correia GSdC, Li S, et al. Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution. Curr Oncol Rep. 2025. doi:10.1007/s11912-025-01655-5.
[3]Dragovich PS. Degrader-antibody conjugates. Chem Soc Rev. 2022 May 23;51(10):3886-3897. doi: 10.1039/d2cs00141a. PMID: 35506708.
[4] Paz-Manrique R, Pinto JA, Gomez Moreno HL. Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action. Hematol Oncol Stem Cell Ther. 2024. doi:10.4103/hemoncstem.HEMONCSTEM-D-24-00042

Note: This article is part of a series: The Magic Bullet, Realized – Antibody-drug Conjugates in Modern Oncology

Featured image: © 2018 Fotolia/Adobe. Used with permission.

DOI